Missouri Settlements Halt Concentrated 7-OH Sales, Signaling Stricter Enforcement for Kratom Industry

Missouri Settlements Halt Concentrated 7-OH Sales, Signaling Stricter Enforcement for Kratom Industry

JEFFERSON CITY, MO – The landscape for kratom merchants and consumers in Missouri has shifted significantly following recent settlements announced by Attorney General Catherine Hanaway. These agreements effectively halt the in-state sale of concentrated 7-hydroxymitragynine (7-OH) and other kratom alkaloids by two major distributors, American Shaman and Relax Relief Rejuvenate Trading LLC. This action underscores a growing regulatory focus on highly potent kratom derivatives, even in the absence of specific legislative bans.

What Happened: Attorney General Hanaway's office initiated litigation in March, alleging that these companies engaged in deceptive marketing practices, including offering "free samples" of 7-OH products without adequately disclosing their addictive nature and potential health risks. The state contended that concentrated 7-OH acts as a dangerous, unregulated opioid, posing serious public health threats.

Under the terms of the settlements, both American Shaman and Relax Relief Rejuvenate Trading LLC have agreed to immediately cease all sales of concentrated 7-OH and other specified kratom alkaloids to Missouri consumers, both in physical stores and online. They must also discontinue all Missouri-targeted retail advertising, including billboards, and implement stringent controls within 30 days to prevent future retail sales in the state. Crucially, any breach of these agreements could result in court orders to halt the conduct and trigger a substantial $5 million penalty. These legal actions come despite Missouri lawmakers debating, but ultimately failing to pass, legislation to ban or regulate 7-OH and kratom products during the recent legislative session.

Why It Matters to Kratom Merchants and Consumers: For consumers, these settlements aim to remove products that the Missouri Department of Health and Senior Services (DHSS) and the FDA have warned against due to their high potency and lack of safety testing. The DHSS has explicitly stated that 7-OH is "engineered to be addictive" and is "13 times stronger than morphine at affecting the body's opioid receptors," carrying risks of addiction, poisoning, and even death.

For kratom merchants, these settlements set a significant precedent. They demonstrate that state authorities are prepared to use existing consumer protection laws to target concentrated kratom alkaloids, particularly 7-OH, and perceived deceptive marketing, even without specific kratom-focused legislation. This signals an elevated regulatory risk for any company involved in the sale or distribution of such products. The focus on marketing practices, especially "free samples" and downplaying addiction risks, highlights areas of extreme vulnerability for businesses.

Compliance Implications: The Missouri Attorney General's successful litigation underscores the critical need for absolute transparency and accuracy in product information and marketing. Any claims regarding the safety, efficacy, or non-addictive nature of kratom products, particularly concentrated derivatives, will face intense scrutiny. The legal emphasis on 7-OH as a "hazardous opioid" means that authorities are drawing a clear distinction between natural kratom and its highly concentrated, potentially synthetically enhanced, alkaloids.

What High-Risk Merchants Need to Know: High-risk kratom merchants, especially those dealing with concentrated alkaloids, must prioritize rigorous compliance measures:

• Certificates of Analysis (COAs) and Lab Testing: Comprehensive third-party lab testing and transparent COAs are no longer just best practices; they are essential for legal defense. COAs must accurately reflect the full alkaloid profile, specifically detailing concentrations of mitragynine and 7-hydroxymitragynine. Merchants must be able to unequivocally prove the contents and purity of their products.
• Transparent Labeling and Disclosure: Full disclosure of all ingredients, active compounds, and their precise concentrations is paramount. Any product containing concentrated 7-OH must be clearly labeled, and its potency and potential risks, including addiction, should be prominently displayed and not minimized.
• Scrupulous Marketing Practices: All marketing claims must be truthful and substantiated. Avoid making unsubstantiated health or therapeutic claims, and be extremely cautious with promotions like "free samples" for potent substances, as this was a specific point of contention in the Missouri lawsuits. Ensure all advertising accurately reflects the product's nature and potential risks.
• Monitor Regulatory Landscape: The Missouri action demonstrates that enforcement can occur even when specific kratom legislation is stalled. Merchants must stay informed about state and federal consumer protection laws, as well as specific health advisories from agencies like the FDA and state health departments.
• Understand Product Differentiation: Recognize that regulators are increasingly distinguishing between raw kratom leaf and highly concentrated, isolated, or synthetically modified alkaloids like 7-OH. The legal and regulatory risks associated with the latter are demonstrably higher.

These Missouri settlements serve as a stark reminder that the regulatory environment for kratom, particularly its concentrated derivatives, is dynamic and subject to aggressive enforcement, demanding heightened vigilance and adherence to robust compliance standards from all merchants.